1. Home
  2. TORO vs STTK Comparison

TORO vs STTK Comparison

Compare TORO & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

HOLD

Current Price

$5.39

Market Cap

84.0M

ML Signal

HOLD

Logo Shattuck Labs Inc.

STTK

Shattuck Labs Inc.

HOLD

Current Price

$3.71

Market Cap

119.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TORO
STTK
Founded
2022
2016
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.0M
119.0M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TORO
STTK
Price
$5.39
$3.71
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$4.00
AVG Volume (30 Days)
993.6K
473.4K
Earning Date
12-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,203,079.00
$1,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$0.69
52 Week High
$5.95
$3.79

Technical Indicators

Market Signals
Indicator
TORO
STTK
Relative Strength Index (RSI) 63.15 79.33
Support Level $5.25 $3.15
Resistance Level $5.71 $3.29
Average True Range (ATR) 0.26 0.22
MACD -0.05 0.03
Stochastic Oscillator 58.46 91.24

Price Performance

Historical Comparison
TORO
STTK

About TORO Toro Corp.

Toro Corp acquires, owns, charters, and operates oceangoing tanker vessels and provides seaborne transportation services for crude oil and refined petroleum products. It operates in three reportable segments: the Aframax tanker, the LPG carrier segment, and the Handysize tanker. The company generates maximum revenue from the Aframax tanker segment.

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Share on Social Networks: